Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ATNF Stock Summary
In the News
Why Is 180 Life Sciences (ATNF) Stock Up 38% Today?
180 Life Sciences (NASDAQ: ATNF ) stock is climbing higher on Wednesday as the cannabis market undergoes a rally. The cannabis sector has been on the rise lately as several companies in it release earnings reports.
Penny Stock Investing, 3 High-Growth Industries to Watch
Take a look at these 3 industries to find penny stocks in The post Penny Stock Investing, 3 High-Growth Industries to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Top Penny Stocks To Watch Today; Time To Buy?
5 hot penny stocks to watch right now. The post 5 Top Penny Stocks To Watch Today; Time To Buy?
Using News to Find Penny Stocks to Buy: 3 Tips
Are you using the news to find penny stocks to buy? The post Using News to Find Penny Stocks to Buy: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
3 Essential Strategies for Penny Stocks Trading in 2023
Are you using these penny stocks trading strategies? The post 3 Essential Strategies for Penny Stocks Trading in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The 7 Most Sold-Off Stocks of 2022
With a contentious time in 2022 coming to a close, it may be helpful to look back and consider the most sold-off stocks last year. Similar to learning from prior mistakes, investors may be able to garner lessons from the worst-hit market ideas.
180 Life Sciences (ATNF) Stock: 1-For-20 Reverse Split Goes Into Effect
A 1-for-20 reverse split of 180 Life Sciences (ATNF) stock has gone into effect. These are the details.
Why 180 Life Sciences Shares Are Plunging Today
180 Life Sciences Corp (NASDAQ: ATNF) received a written response from the U.K.'s regulatory agency and U.S. FDA related to questions submitted in a Type C meeting request for anti-TNF treatment, adalimumab, to treat early-stage Dupuytren's disease. Dupuytren's disease.
180 Life Sciences (ATNF) Stock: Why The Price Jumped Up Today
The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 11% pre-market today. This is why it happened.
ATNF Financial details
ATNF Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | -46.02 | -11.99 | -12.96 | -20.38 | |
Operating cash flow per share | 0 | -6.01 | -4.27 | -12.36 | -6.38 | |
Free cash flow per share | 0 | -6.28 | -4.27 | -12.36 | -6.38 | |
Cash per share | 0 | 21.68 | 2.32 | 5.25 | 3.67 | |
Book value per share | 0 | 69.9 | 33.37 | 25.08 | 5.97 | |
Tangible book value per share | 0 | -22.67 | -23.39 | -7.78 | 0.33 | |
Share holders equity per share | 0 | 69.9 | 33.37 | 25.08 | 5.97 | |
Interest debt per share | 0 | 6.73 | 5.36 | 1.37 | 0.72 | |
Market cap | 0 | 324.99M | 941.65M | 2.32B | 122.4M | |
Enterprise value | -270.88K | 328.43M | 943.32M | 2.32B | 116.77M | |
P/E ratio | 0 | -12.8 | -86.52 | -114.32 | -3.16 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | -97.93 | -243.2 | -119.94 | -10.09 | |
PFCF ratio | 0 | -93.84 | -243.2 | -119.94 | -10.09 | |
P/B Ratio | 0 | 8.43 | 31.09 | 59.09 | 10.79 | |
PTB ratio | 0 | 8.43 | 31.09 | 59.09 | 10.79 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 31.06 | -15.97 | -179.41 | -156.99 | -6.56 | |
EV to operating cash flow | 0.34 | -98.97 | -243.63 | -119.62 | -9.63 | |
EV to free cash flow | 0.34 | -94.84 | -243.63 | -119.62 | -9.63 | |
Earnings yield | 0 | -0.08 | -0.01 | -0.01 | -0.32 | |
Free cash flow yield | 0 | -0.01 | 0 | -0.01 | -0.1 | |
Debt to equity | 0 | 0.09 | 0.12 | 0.05 | 0.12 | |
Debt to assets | 0 | 0.07 | 0.07 | 0.03 | 0.07 | |
Net debt to EBITDA | 31.06 | -0.17 | -0.32 | 0.42 | 0.32 | |
Current ratio | 0.5 | 0.08 | 0.19 | 0.57 | 1.58 | |
Interest coverage | 0 | -112.69 | -5.2 | -84 | -671.17 | |
Income quality | -0.76 | 0.13 | 0.36 | 0.95 | 0.31 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.04 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.98 | 0.93 | 0.82 | 0.55 | |
Capex to operating cash flow | 0 | 0.04 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -2 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 269.05 | 94.88 | 85.53 | 52.32 | |
ROIC | 0 | -0.5 | -0.17 | -0.38 | -1.38 | |
Return on tangible assets | 0 | -31.64 | -2.71 | -1.81 | -4.34 | |
Graham Net | 0 | -1.73 | -24.23 | -8.63 | -0.62 | |
Working capital | -275.18K | -8.89M | -17.41M | -8.5M | 3.27M | |
Tangible asset value | 113.87M | -12.51M | -21.23M | -12.19M | 622.06K | |
Net current asset value | -4.3M | -12.57M | -21.23M | -12.19M | 622.06K | |
Invested capital | 0 | 0.09 | 0.12 | 0.05 | 0.12 | |
Average receivables | 0 | 164.17K | 556.49K | 739.6K | 657.76K | |
Average payables | 0 | 2.05M | 6.32M | 4.56M | 1.19M | |
Average inventory | 0 | 150.78K | 704.45K | 1.67M | 805.65K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 20.73K | 24.84K | 1.84K | 6.03K | |
Days of inventory on hand | 0 | 1.52K | 3.22K | 7.01K | -2.08K | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.02 | 0.01 | 0.2 | 0.06 | |
Inventory turnover | 0 | 0.24 | 0.11 | 0.05 | -0.18 | |
ROE | 0 | -0.66 | -0.36 | -0.52 | -3.41 | |
Capex per share | 0 | -0.26 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -19.87 | -9.75 | -1.26 | -0.7 | -1.29 | |
Operating cash flow per share | -1.84 | -1.31 | -1.03 | -0.6 | -0.22 | |
Free cash flow per share | -1.84 | -1.31 | -1.03 | -0.6 | -0.22 | |
Cash per share | 1.83 | 3.12 | 0.71 | 0.38 | 0.33 | |
Book value per share | 13.31 | 5.08 | 1.91 | 1.28 | -0.02 | |
Tangible book value per share | -0.89 | 0.28 | -0.96 | -0.77 | -0.22 | |
Share holders equity per share | 13.31 | 5.08 | 1.91 | 1.28 | -0.02 | |
Interest debt per share | 0.23 | 0.6 | 0.24 | 0.12 | 0.05 | |
Market cap | 495.06M | 143.7M | 128.15M | 116.29M | 92.56M | |
Enterprise value | 491.91M | 138.07M | 126.38M | 114.9M | 90.25M | |
P/E ratio | -3.18 | -1.65 | -6.77 | -7.9 | -2.25 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -137.66 | -49.1 | -33.12 | -37.31 | -52.13 | |
PFCF ratio | -137.66 | -49.1 | -33.12 | -37.31 | -52.13 | |
P/B Ratio | 18.99 | 12.67 | 17.95 | 17.32 | -619.85 | |
PTB ratio | 18.99 | 12.67 | 17.95 | 17.32 | -619.85 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -121.54 | -24.64 | -26.43 | -31.44 | -25.75 | |
EV to operating cash flow | -136.78 | -47.18 | -32.66 | -36.86 | -50.83 | |
EV to free cash flow | -136.78 | -47.18 | -32.66 | -36.86 | -50.83 | |
Earnings yield | -0.08 | -0.15 | -0.04 | -0.03 | -0.11 | |
Free cash flow yield | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | |
Debt to equity | 0.02 | 0.12 | 0.12 | 0.09 | -2.38 | |
Debt to assets | 0.01 | 0.07 | 0.06 | 0.04 | 0.07 | |
Net debt to EBITDA | 0.78 | 1 | 0.37 | 0.38 | 0.66 | |
Current ratio | 1.38 | 1.58 | 0.82 | 0.69 | 0.7 | |
Interest coverage | -456.46 | -1.24K | -415.7 | -317.33 | -304.12 | |
Income quality | 0.17 | 0.13 | 0.81 | 0.85 | 0.17 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.81 | 0.55 | 0.72 | 0.79 | 0.32 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 77.13 | 33.39 | 7.36 | 4.51 | 0.74 | |
ROIC | -0.28 | -0.43 | -0.6 | -0.5 | -14 | |
Return on tangible assets | -5.97 | -2.44 | -1.13 | -1.25 | -3.05 | |
Graham Net | -2.06 | -0.53 | -1.35 | -0.94 | -0.3 | |
Working capital | 1.79M | 3.27M | -925.57K | -1.34M | -1.44M | |
Tangible asset value | -1.75M | 622.06K | -3.59M | -4.02M | -1.74M | |
Net current asset value | -1.75M | 622.06K | -3.59M | -4.02M | -1.74M | |
Invested capital | 0.02 | 0.12 | 0.12 | 0.09 | -2.38 | |
Average receivables | 2.27M | 1.57M | 489.23K | 223.49K | 109.95K | |
Average payables | 1.3M | 1.41M | 1.5M | 1.02M | 1.28M | |
Average inventory | -767.03K | -1.57M | -489.23K | -223.49K | -109.95K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 11.46K | 4.31K | 4.99K | 2.64K | 4.72K | |
Days of inventory on hand | -28.33K | -1.49K | -1.48K | -282.08 | -359 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.02 | 0.02 | 0.03 | 0.02 | |
Inventory turnover | 0 | -0.06 | -0.06 | -0.32 | -0.25 | |
ROE | -1.49 | -1.92 | -0.66 | -0.55 | 68.75 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ATNF Frequently Asked Questions
What is 180 Life Sciences Corp. stock symbol ?
180 Life Sciences Corp. is a US stock , located in Palo alto of Ca and trading under the symbol ATNF
What is 180 Life Sciences Corp. stock quote today ?
180 Life Sciences Corp. stock price is $2.01 today.
Is 180 Life Sciences Corp. stock public?
Yes, 180 Life Sciences Corp. is a publicly traded company.